Business pitch book/Teaser

Our company focuses on developing affordable and real-needed medical products. Our business area including medical device, and pharmaceutical development.

We are leading in Oral delivery of peptide & protein drugs. Our research team have more than 20 years experience in developing the oral insulin in Tsinghua University. We had developed the first oral insulin approved under Phase III clinical in China.

We established our own company in 2014, and now we hold one R&D Center and one GMP-standard Medical Device Manufacturing Enterprises.

One of the most promising subject in our research pipeline is oral delivery of PTH1-34, a peptide molecule used in osteoporosis therapy. Currently, PTH1-34 is available only by injection delivery daily for 18-24 months, expensive and painful. In pre-clinical study, our oral PTH1-34 has demonstrated a significant increase in bone formation, and the bioavailability 12%, which is higher than any other published results. This novel oral PTH1-34 could be a more affordable and convenient option for the treatment of osteoporosis.

As regarded to the medical devices, we now have been approved 32 Class II medical devices by the end of 2018. Our products were introduced into market in September 2018, the sales are over 5 million Yuan in 2018.

I will be very honored if I am selected to join the GES, I am glad to share my experience and seek the opportunity to cooperate with friends all over the world.